Shire gives attention to deficit of comparative data in ADHD and beyond
This article was originally published in Scrip
In what is destined to become a mantra for specialty biopharmaceutical company Shire across a range of its products, the company plans to identify the value differential of its treatment for attention deficit hyperactivity disorder Vyvanse against a competitor, Johnson & Johnson's Concerta.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.